Skip to main content

Clinical Trial Search Results

Clinical Trial Search Results

Showing 1-9 out of 399 results.
NCT3978689

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Icon for trial | CUE-101-01 A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous C

This study is currently enrolling.

Historically, patients with recurrent or metastatic head and neck cancer (HNSCC) have been treated with combinations of chemotherapeutic drugs. Recent studies with immunotherapy drugs that inhibit the programmed cell death 1 ( ...

NCT03926130

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease.

Icon for trial | I6T-MC-AMAM A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease.

This study is currently enrolling.

The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research questions: How safe mirikizumab is and whether you might have any side effects when you t ...

NCT04026412

A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Duravalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

Icon for trial | CA209-73L A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Duravalumab in Previously Untreated, Loc

This study is currently enrolling.

The purpose of this study is to evaluate the effectiveness (how well the drug(s) work), safety, and tolerability of adding the investigational drug, Nivolumab, to concurrent chemoradiotherapy followed by treatment with Nivoluma ...